A groundbreaking innovation from the University of Saskatchewan could potentially reduce the length of calving season for beef producers. The discovery involves the use of Cetrorelix, a hormone drug originally utilized in human in vitro fertilization (IVF) procedures, which has shown great promise in the cattle industry based on research conducted at the university in Saskatoon.
Dr. Jaswant Singh, a veterinary medicine expert and researcher at the Western College of Veterinary Medicine, stumbled upon the potential of Cetrorelix during a study eight years ago. Working alongside graduate students Dylan Farmer and Carlos Leonardi, Singh tested the drug on 200 cows and achieved remarkable results.
The drug acts as an ovulation synchronization method, facilitating a synchronized pregnancy process in cows through IVF within a short timeframe. This synchronization could lead to a more concentrated calving period, offering potential benefits in terms of reduced labor costs and improved animal management.
Garner Deobald, a beef rancher and marketing manager at BoviGen Genetic Services, expressed enthusiasm about the potential of Cetrorelix to enhance breeding practices in the industry. If proven effective, the drug could serve as a valuable tool for both individual cattle operations and larger reproduction centers like BoviGen.
Furthermore, the use of Cetrorelix may promote artificial insemination as a more appealing breeding technique compared to traditional methods. This shift could result in increased focus on genetic traits within herds and provide more reliable information on expected calf outcomes.
Dr. Singh revealed that the university has filed a patent for the drug and is collaborating with pharmaceutical companies to bring it to market. He expressed optimism about the widespread adoption of Cetrorelix, emphasizing its potential to revolutionize breeding practices not only in Saskatchewan but globally.
The progress with Cetrorelix has already cleared significant regulatory hurdles, with the focus now shifting towards optimizing its application in animals. The affordability of the drug is also a key consideration, as it aims to meet the financial expectations of livestock producers while delivering tangible benefits in cattle breeding practices.
